Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 10, 2026
ProShares UltraPro Russell 2000 (URTY) Delivers +13.7% as Small-Cap Rally Broadens

ProShares UltraPro Russell 2000 (URTY) Delivers +13.7% as Small-Cap Rally Broadens

Key Takeaways

  • URTY surged approximately 13.7% over the last 30 days, amplifying a powerful small-cap equity rally through its 3x daily leveraged exposure to the Russell 2000 Index.
  • The Russell 2000 completed its strongest first half since 1991, gaining 22% year-to-date, as the artificial intelligence investment cycle broadened beyond mega-cap technology companies into smaller suppliers and semiconductor equipment firms.
  • Over the last quarter, URTY delivered a substantially magnified return as the underlying index climbed more than 21% during the second quarter of 2026 alone.
  • Key catalysts included improving small-cap earnings estimates, a narrowing valuation gap versus large-cap stocks, and a US-brokered peace agreement with Iran that helped ease energy price pressures.
  • Semiconductor and semiconductor equipment names accounted for 16 of the Russell 2000's 50 best-performing stocks during the first half, directly benefiting URTY's leveraged exposure.

URTY ETF Overview and Portfolio Exposure

URTY is a leveraged exchange-traded fund that seeks daily investment results, before fees and expenses, corresponding to three times the daily performance of the Russell 2000 Index. The fund launched in February 2010, carries a net expense ratio of 0.95%, and manages approximately $352 million in net assets. It is designed as a short-term trading tool rather than a buy-and-hold investment, since daily compounding and leverage decay can cause returns over periods longer than one day to deviate significantly from three times the index return.

The Russell 2000 Index tracks roughly 1,900 to 2,000 small-capitalization US companies with an average market capitalization of about $1.5 billion to $1.8 billion. URTY obtains its leveraged exposure mainly through total return swap agreements with major financial institutions, along with a portfolio of individual small-cap holdings and futures contracts. Sector weightings in the underlying index are led by Financials at approximately 19.3%, followed by Industrials (17.1%), Health Care (16.0%), Information Technology (14.7%), and Consumer Discretionary (10.1%). This diversified small-cap mix means URTY’s performance is heavily influenced by domestic economic conditions, as small-cap companies typically generate 70% to 80% of their revenue inside the United States.

URTY Price Performance: Last 30 Days vs. the Quarter

Over the last 30 days, URTY climbed from a closing price of $72.70 on June 10, 2026, to approximately $82.69 as of July 10, 2026, representing a gain of roughly 13.7%. The move was not linear; the fund saw notable intra-period volatility, including a sharp rally in mid-June that pushed prices above $85, followed by a pullback in early July as profit-taking hit semiconductor names. The Russell 2000 itself reached a fresh all-time high above 3,046 during this window, providing strong tailwinds for the 3x leveraged fund.

Over the last quarter, performance was even more pronounced. The Russell 2000 Index gained approximately 21.5% during the second quarter of 2026 alone, its strongest quarterly showing in years. URTY, applying 3x daily leverage to that move, delivered a substantially magnified quarterly return. The three-month period captured a broad rotation into small-cap equities driven by improving earnings fundamentals, AI supply-chain expansion, and a favorable macroeconomic backdrop that included easing oil prices following diplomatic progress with Iran.

What Drove URTY Higher in the Last 30 Days

The primary driver of URTY’s 30-day advance was the continued outperformance of small-cap stocks relative to large-cap benchmarks. The Russell 2000’s rally was fueled by growing investor conviction that the artificial intelligence investment cycle is broadening well beyond the mega-cap technology companies that dominated market returns from 2023 through early 2025. Smaller semiconductor equipment manufacturers, testing companies, and specialized component suppliers have emerged as significant beneficiaries, with names such as AEHR (Aehr Test Systems), ICHR (Ichor Holdings), and MXL (MaxLinear) each surging more than 400% year-to-date.

Macroeconomic developments also provided support. The June nonfarm payrolls report showed only 57,000 jobs added against expectations of 115,000, which reduced near-term fears of additional Federal Reserve interest rate hikes. Lower rate expectations tend to benefit small-cap stocks, which generally carry more floating-rate debt than their large-cap counterparts. Additionally, the US-brokered peace agreement with Iran contributed to declining oil prices, a development that Invesco’s head of factor strategy noted could accelerate the profitability recovery for small-cap companies by reducing input and transportation costs.

Institutional flows into small-cap ETFs accelerated throughout the period, reflecting a structural rotation as the valuation gap between small and large caps narrowed from historically extreme levels. Consensus earnings growth estimates for Russell 2000 companies rose from approximately 23% to 38% during the first half of 2026, providing fundamental justification for the rally. I also checked sector leadership trends using Tickeron’s AI Screener to see how the small-cap names compared on momentum metrics.

What Drove URTY Performance Over the Last Quarter

The broader three-month trend reflects a structural regime change in US equity markets. After years of large-cap dominance, small-cap stocks began outperforming in early 2025, and that leadership accelerated through the second quarter of 2026. The Russell 2000 posted a 21.5% quarterly gain, with all 11 sectors finishing in positive territory. Information Technology was the standout sector, followed by Industrials, Health Care, and Financials, each making meaningful contributions to index performance.

Earnings growth has been the primary engine. Research from Royce Investment Partners indicates that more than 60% of the Russell 2000’s year-to-date and one-year returns through June 30 were attributable to earnings per share (EPS) growth rather than multiple expansion. This earnings-driven advance distinguishes the current rally from purely speculative episodes and has attracted institutional investors who had been underweight small-cap equities for much of the past decade. The AI buildout, which initially benefited only the largest technology companies, has progressively filtered through to smaller companies providing differentiated products and services across the semiconductor, energy, and construction segments of the AI supply chain.

AI Screener

Identifying ETFs and stocks with strong momentum or sector leadership can be challenging in fast-moving markets. Tickeron’s AI Screener is an AI-powered discovery platform that helps investors scan thousands of securities using technical indicators, fundamental metrics, volatility measures, AI-generated signals, and customizable industry filters. The platform enables users to surface trending securities, breakout candidates, and new trading opportunities more efficiently than manual screening. For investors seeking to monitor small-cap momentum, sector rotation patterns, or leveraged ETF opportunities, the AI Screener provides a structured, data-driven approach to idea generation. In my own process, this tool has been useful for quickly surfacing comparable names when evaluating leveraged small-cap exposure like URTY.

URTY ETF Outlook: What Investors Should Watch Next

Several factors will influence URTY’s trajectory over the coming months. The Federal Reserve’s interest rate path remains the most consequential variable for small-cap equities. While the soft June employment report reduced immediate tightening concerns, any upside surprises in inflation data or economic growth could revive rate hike expectations, disproportionately affecting leveraged small-cap exposure. Bank of America has estimated that every additional 25-basis-point rate increase reduces Russell 2000 operating earnings by approximately 2%.

The annual Russell index rebalancing, which took effect in late June, removed 43 of the index’s strongest-performing companies that graduated into the large-cap Russell 1000. Historical patterns suggest small-cap stocks have tended to give back a portion of their pre-rebalance outperformance in the weeks following the reshuffle. Additionally, the Russell 2000’s forward price-to-earnings ratio has expanded to approximately 26.4, exceeding the S&P 500’s multiple, which may temper further valuation-driven upside.

On the positive side, earnings growth estimates continue to be revised upward, and the AI investment cycle shows few signs of slowing. Small-cap valuations relative to large caps, while narrower than at the start of the year, remain below long-term averages on an enterprise-value-to-EBIT basis. Investors should also monitor geopolitical developments, energy prices, and the pace of AI-related capital expenditure, as these factors will directly affect the small-cap companies that increasingly drive URTY’s underlying index performance. As a 3x daily leveraged product, URTY is designed for short-term trading, and investors holding the fund for periods longer than a single trading session should monitor their positions closely given the effects of compounding and volatility decay. From what I see, these variables will determine whether the recent rotation sustains or pauses in the months ahead.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: URTY

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


Momentum Indicator for URTY turns positive, indicating new upward trend

URTY saw its Momentum Indicator move above the 0 level on August 03, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 93 similar instances where the indicator turned positive. In of the 93 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for URTY just turned positive on August 04, 2026. Looking at past instances where URTY's MACD turned positive, the stock continued to rise in of 47 cases over the following month. The odds of a continued upward trend are .

URTY moved above its 50-day moving average on August 03, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for URTY crossed bullishly above the 50-day moving average on August 07, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where URTY advanced for three days, in of 314 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where URTY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

URTY broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for URTY entered a downward trend on August 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Notable companies

The most notable companies in this group are Bloom Energy Corp (NYSE:BE), Guardant Health (NASDAQ:GH), Arrowhead Pharmaceuticals (NASDAQ:ARWR), SSR Mining (NASDAQ:SSRM), Lumen Technologies (NYSE:LUMN), Transocean Ltd (NYSE:RIG), Valaris Limited (NYSE:VAL), Abercrombie & Fitch Co (NYSE:ANF), California Resources Corp (NYSE:CRC), Tanger (NYSE:SKT).

Industry description

The investment seeks daily investment results that correspond to three times (3x) the daily performance of the Russell 2000® Index. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is designed to measure the performance of the small-cap segment of the U.S. markets. Under normal circumstances, the fund will obtain leveraged exposure to at least 80% of its total assets in components of the index or in instruments with similar economic characteristics. The fund is non-diversified.

Market Cap

The average market capitalization across the ProShares UltraPro Russell2000 ETF is 2.6B. The market cap for tickers in the group ranges from 455.89K to 64.6B. BE holds the highest valuation in this group at 64.6B. The lowest valued company is ZSPC at 455.89K.

High and low price notable news

The average weekly price growth across all stocks in the ProShares UltraPro Russell2000 ETF was 78%. For the same ETF, the average monthly price growth was 114%, and the average quarterly price growth was 2,674%. REPL experienced the highest price growth at 138%, while MVIS experienced the biggest fall at -94%.

Volume

The average weekly volume growth across all stocks in the ProShares UltraPro Russell2000 ETF was 11%. For the same stocks of the ETF, the average monthly volume growth was 10% and the average quarterly volume growth was -23%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 54
P/E Growth Rating: 57
Price Growth Rating: 51
SMR Rating: 75
Profit Risk Rating: 76
Seasonality Score: -19 (-100 ... +100)
View a ticker or compare two or three
URTY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Leveraged Equity
Address
ProShares Trust7501 Wisconsin Avenue,Suite 1000Bethesda
Phone
N/A
Web
www.proshares.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.